NEOGENOMICS INC — Director's Dealing 2021

Jun 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-06-02

Reporting Person: CARDOZA GEORGE (President, Pharma Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-02	Common Stock	S	169230	$40.39	Disposed	207879	Direct
2021-06-03	Common Stock	S	31107	$40.11	Disposed	176772	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$7.52	2022-04-28	Common Stock (50000.0)	50000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (192500.0)	192500	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (51459.0)	51459	Direct
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (48768.0)	48768	Direct
Stock Option (Right to Buy)	$53.17	2028-03-02	Common Stock (35171.0)	35171	Direct

Footnotes

F1: On April 28, 2017, Mr. Cardoza was granted 200,000 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F2: On February 26, 2018, Mr. Cardoza was granted 192,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F3: On March 1, 2019, Mr. Cardoza was granted 51,459 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F4: On March 2, 2020, Mr. Cardoza was granted 48,768 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2021, Mr. Cardoza was granted 35,171 stock options. These options vest ratably over the first four anniversary dates of the grant date.